Blood test could spot lingering lung cancer after surgery

NCT ID NCT05254782

Recruiting now Knowledge-focused Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a liquid biopsy (a blood test that looks for cancer DNA) can find tiny amounts of leftover cancer in people who have had surgery for early-stage non-small cell lung cancer. The goal is to see if this test can predict which patients might have their cancer come back, so they can get additional treatment sooner. The study will enroll 360 participants across multiple hospitals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liquid biopsy (ctDNA detection)
What this could lead to: If successful, this approach could help identify lung cancer patients at high risk of recurrence after surgery, guiding them to additional curative treatment earlier.
What could go wrong: This is an early-stage observational study, not a treatment trial. The ctDNA test may not reliably predict recurrence, and results may not change outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Michael Garron Hospital
RECRUITING

Toronto, Ontario, Canada
St. Joseph's Health Centre
RECRUITING

Toronto, Ontario, Canada
University Health Network
RECRUITING

Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.